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community hospitals as models in areas such as following: to improve efficiency by
downsizing the scale of the hospitals, to adopt new marketing strategies, and to
change the cost structure of facility operations. CONCLUSIONS: Results of this
work can be useful for guidance to hospital CEOs and administrators, creditors and
bondholders, health care consultants, public finance and public accounting re-
searchers, public policy analysts, and the government; to gain insights of this issue
of hospital’s economic performance along the above mentioned variables.
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OBJECTIVES: The aim of the study is to show the change in important parameters
of intensive care units in Hungary from the year 2000 to 2010. METHODS: Data of
the analysis was taken from the financial database of the Hungarian National
Health Insurance Fund Administration, the only health care agency in Hungary.
We analyzed the number of hospital beds at intensive care units, the number of
intensive care units, their average bed numbers, market share. RESULTS: The Hun-
garian health care system has had 150-167 intensive care units all over the country.
The teaching and some county hospitals had more then one ICU. That meant
1183-1430 beds during the 10 years. We found the highest number of intensive care
beds in 2006 (1430) which was significantly decreased in 2007-2008 below 1300
beds. The median range of beds at a typical ICU was between 5-9. The market share
of intensive care hospital beds form the total number of acute care hospital beds
increased from 1.8 % in 2000 to 2.9 % in 2011. The proportion of day provided with
ventilation also significantly increased from 29 % in 2000 to 68 % in 2010.
CONCLUSIONS: In Hungary the number of the ICUs and the number of the ICUs’
bed did not change significantly in the last 10 years. During this period, the rate of
the ventilation increased. The Hungarian intensive care units successfully man-
aged to adapt to the changing hospital environment.
Health Care Use & Policy Studies – Health Technology Assessment Programs
PHP115
PRELIMINARY ANALYSIS OF THE UNWRITTEN DECISION RULES BEHIND THE
FRENCH TRANSPARENCY COMMISSION’S ASSESSMENT OF DRUGS
Toumi M1, Michel M2, Mraidi M3, Rahmouni A3, Duvillard R3
1University Claude Bernard Lyon 1, Lyon, France, 2University Paris Descartes, Paris, France,
3Creativ-Ceutical, Paris, France
OBJECTIVES: Our objective was to analyze the French HTA decision making pro-
cess of the Transparency Commission (TC) and try to identify unwritten decision
rules which influence a drug’s SMR and ASMR. METHODS: We analyzed the TC
database for the years 2005 to 2010, looking at key points of the TC’s opinions listed
within such as: SMR, ASMR, target population, public health impact, presence of
alternatives, orphan drug status, prescription restriction etc. Using a bivariate
analysis we compared drugs granted: insufficient SMR versus other SMR; ASMR V
versus ASMR IV; ASMR IV versus ASMR I, II and III. RESULTS: We found that drugs
granted an ASMR V more often had alternatives than drugs with an ASMR IV
(89.74% vs. 69.82%, p0.005), while prescription of drugs with an ASMR IV was more
often restricted than for drugs with an ASMR V (p0.01 for hospital-only prescrip-
tion and p0.005 for specialist prescription). The median target population for
drugs with an ASMR IV was also smaller than for an ASMR V (15,000 vs. 97,250). On
the other hand drugs with an ASMR IV more often had no public health impact than
those with an ASMR I-III (55.70% vs. 22.13%, p0.005). Drugs with a high ASMR had
smaller median target population (3,400 vs. 15,000) although there was no differ-
ence in orphan drug status between the two groups (9.47% for ASMR IV vs. 14.07%
for ASMR I-III, p0.20). More drugs with ASMR I-III were paediatric medicines
(30.04% vs. 14.79%, p0.005). CONCLUSIONS: Further analyses are in progress us-
ing additional qualitative criteria extracted from the TC’s opinions and using a
multivariate analysis. Such information would be critical for the development of
TC application dossier.
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OBJECTIVES: To understand how different evidence bases may contribute to
health technology assessment (HTA) across jurisdictions, we reviewed the evi-
dence considered by three HTA agencies supporting reimbursement recommen-
dations for nine drugs. METHODS: We selected nine drugs for which the Canadian
Common Drug Review (CDR), the Australian Pharmaceutical Benefits Advisory
Committee (PBAC), and the National Institute for Health and Clinical Excellence
(NICE) had each provided recent reimbursement recommendations. We reviewed
the clinical and economic evidence considered for each decision and evaluated
whether different evidence bases could have contributed to different HTA
decisions. RESULTS: The three HTA agencies agreed (recommended to reimburse)
for four drugs and reached different recommendations for five drugs. In both cat-
egories, somewhat different evidence bases were used by each agency. For a given
drug, different comparators were sometimes considered by different agencies.
Even when comparators were common across agencies, there was variability re-
garding which clinical trials were considered. All agencies considered data from
direct, randomized trials, but PBAC and NICE accepted indirect comparisons,
whereas CDR did not. Regarding economic outcomes, all NICE decisions made use
of cost-effectiveness (mostly cost-utility) analyses, but cost-minimization ap-
proaches were considered by CDR and PBAC for several drugs. Overall, NICE pro-
vided the most transparent reporting on decision making, and CDR was generally
the least transparent of the three. CONCLUSIONS: HTA drug decisions across the
three countries lack good agreement, and considerable variability exists in the
clinical and economic bases considered by CDR, PBAC, and NICE. The reluctance of
CDR to accept indirect clinical comparisons, and the propensity of NICE to heed
expert advice when analyses were inconclusive may contribute to dissimilar deci-
sions being reached for some drugs. Greater transparency and harmonization of
HTA methods have the potential to improve efficiency in health care decision-
making, and further research analyzing additional HTA drug decisions is war-
ranted.
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OBJECTIVES: To review the existing literature on; i) the definition of the threshold
ii) debate about its use, theory and value and, iii) robust theoretical methods for its
calculation. METHODS: The traditional approach for literature searching makes
use of key terms and Medical Subject Headings (MeSH) that most accurately cap-
ture the range of literature relevant to the piece of work while attempting to min-
imize irrelevant studies. This process requires a degree of expertise (and luck) as to
the terms used, with the potential of missing related but differently specified areas
of the literature and anything not captured in search engines. The alternative
approach is “pearl growing”. This approach uses a pool of relevant papers (“initial
pearls”) to grow the literature both through references and citations until all rele-
vant papers have been discovered. This approach therefore relies on the expertise
of the authors of the published literature rather than the searcher’s knowledge of
applicable terms. RESULTS: The traditional method of searching yielded 34 papers,
only 17 of which were deemed relevant. In comparison pearl growing resulted in
the identification of 76 relevant papers, including all of the 17 papers identified
under the traditional strategy. The focus of many of these papers was to debate the
use of a threshold, the theory underlying it or its value. A small number focused on
methods for estimating its value, with a large majority using the social
willingness-to-pay. CONCLUSIONS: The “pearl growing” approach offers a range of
benefits over traditional methods, including the identification of papers and dis-
tinct sections of the literature not discovered otherwise, although it is limited by
the existing software. The cost-effectiveness threshold has been heavily debated,
but there exists very little literature that attempts to provide a meaningful estimate
of its value or even provide a theoretical framework for its calculation.
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OBJECTIVES: Since 2007, HTA environment has been introduced to evaluate new
drug’s pricing & reimbursement in Korea, and PE submission became one of man-
datory requirements in HIRA (Health Insurance Review Agency). The objective of
this study is to understand the overall process and result under the current envi-
ronment, and to identify factors in the process which might cause a patient access
issue. METHODS: We reviewed DREC (Drug Reimbursement Evaluation Commit-
tee)’s result reports (n97) of new products from August 2007 to November 2010,
which is open to the public. RESULTS: Among total 97 cases, the number of reim-
bursement decision was 58 (59.8%) at HIRA. The majority of reason for reimburse-
ment decision was lower treatment cost (67.2%). DREC accepted only 12 cases’ ICER
value for reimbursement decision, 85 decisions were made without PE result data.
Although clinical usefulness was improved in 33 cases, non-reimbursement deci-
sion was made in 6 cases because cost-effectiveness or PE data was uncertain.
Among 39 cases of non-reimbursement decisions, 10 cases accepted WAP
(Weighted Average Price) that HIRA suggested. Success rate of price negotiation at
NHIC was 68.0%, and took 3.7 months including administrative process from DREC
decision to MOHW (Ministry of Health and Welfare)’s final announcement. Average
duration for final reimbursement decision was 16.9 months. Approximately 7 more
months were necessary for applicant with PE data rather than without PE data (22.0
months vs. 15.0 months). CONCLUSIONS: The aim for introducing HTA is to list
drugs which prove clinical usefulness and cost effectiveness but this analysis
shows that it is difficult to expedite patient access to medicine through a HTA
environment in Korea. Alternatives beyond PE evidence are needed for timely pa-
tients’ access to innovative drugs.
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